Area of research
Cancer Research · Oncology
Research interest
Research interests include Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, and Advanced Breast Cancer Therapies.
A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.
Non-inferiority trials: tyranny or good governance? - Authors' reply.
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data.
315P SYNERGIA breast cancer: Automated assessment of tumour-infiltrating lymphocytes
The Lancet Breast Cancer Commission
The Lancet Breast Cancer Commission.
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
The tyranny of non-inferiority trials.
Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
Abstract CT012: PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC)
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Multi-omic machine learning predictor of breast cancer therapy response.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge.
PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer.
Magnetization transfer imaging of ovarian cancer: initial experiences of correlation with tissue cellularity and changes following neoadjuvant chemotherapy.
Abstract OT2-24-01: PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
Magnetization transfer imaging of ovarian cancer: initial experiences of correlation with tissue cellularity and changes following neoadjuvant chemotherapy
Abstract CT562: PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of Olaparib to Platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
Multi-omic machine learning predictor of breast cancer therapy response
LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer
Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK.
Profiteering from vaccine inequity: nudge pharma towards "doing well by doing good".
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis